Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

STIM - Neuronetics Inc


IEX Last Trade
0.8849
0.035   3.955%

Share volume: 91,526
Last Updated: Fri 30 Aug 2024 09:59:16 PM CEST
Surgical and Medical Instrument Manufacturing : -0.56%

PREVIOUS CLOSE
CHG
CHG%

$0.85
0.04
4.12%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
13%
Profitability 8%
Dept financing 24%
Liquidity 71%
Performance 0%
Company vs Stock growth
vs
Performance
5 Days
-8.49%
1 Month
-52.01%
3 Months
-53.52%
6 Months
-70.27%
1 Year
-45.82%
2 Year
-76.13%
Key data
Stock price
$0.88
P/E Ratio 
-0.82
DAY RANGE
N/A - N/A
EPS 
-$1.11
52 WEEK RANGE
$0.66 - $5.07
52 WEEK CHANGE
-$0.46
MARKET CAP 
26.754 M
YIELD 
N/A
SHARES OUTSTANDING 
30.295 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/05/2024
BETA 
1.55
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$298,239
AVERAGE 30 VOLUME 
$741,858
Company detail
CEO:
Region: US
Website: http://www.neuronetics.com
Employees: 246
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Surgical and Medical Instrument Manufacturing
Sector: Manufacturing

with neurostar advanced therapy, neuronetics, inc., is the market leader in transcranial magnetic stimulation technology for the treatment of major depressive disorder. based in malvern, pa, we are a privately held medical device company focused on developing non-invasive therapies for psychiatric and neurological disorders using mri-strength magnetic field pulses. we are the first company to have a non-systemic and non-invasive depression treatment cleared by the fda for patients who have not benefited from prior antidepressant medication. neuronetics markets neurostar advanced therapy throughout the united states and select markets around the world. if you have questions or comments about neurostar, please e-mail us at customersupport@neuronetics.com. for u.s. phone support, please call us at (877) 600-7555, for international customers, our number is +1 (610) 640-4207.

Recent news